What insurance policy changes affect code I21.A9?

There are 5 tracked policy changes affecting code I21.A9, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I21.A9?

Payers that have issued tracked updates for code I21.A9 include: Aetna.

How do I get notified when code I21.A9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I21.A9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I21.A9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

I21.A9 Insurance Policy Changes

ICD-10 I21.A9 is officially defined as "Other myocardial infarction type." code I21.A9 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I21.A9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Transmyocardial and Endovascular Laser Revascularization (CPB 0163, reviewed 2026-03-20)
Aetna's Clinical Policy Bulletin 0163 considers open chest and thoracoscopic transmyocardial laser revascularization (TMLR) medically necessary for the treatment of medically refractory, severe intractable angina, when the appendix selection criteria are met. Excimer laser coronary angioplasty for all indications, percutaneous TMLR for refractory angina and all other indications, and TMLR plus cell therapy with adipose derived stromal cells or autologous bone marrow cells for ischemic heart disease are considered experimental, investigational or unproven because their effectiveness has not been established. TMLR by thoracotomy (CPT 33140 and 33141) is listed as covered for ICD-10 angina pectoris codes I20.1 through I20.9 when the selection criteria are met.
Aetna · Identified Aug 18, 2026Medium impact
Holter Monitors (CPB 0019, reviewed 2026-03-13)
Aetna considers Holter monitoring medically necessary for diagnostic evaluation of adult members with listed conditions, including palpitations, syncope or near syncope, unexplained dizziness, and possible or documented long QT syndrome, and for asymptomatic congenital complete atrioventricular block in pediatric patients. Holter monitoring is considered experimental, investigational, or unproven for all other indications because its effectiveness for those indications has not been established. CPT codes 93224, 93225, 93226 and 93227 are covered if the selection criteria are met.
Aetna · Identified Aug 14, 2026Medium impact
Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna · Identified Aug 14, 2026Medium impact
Pulmonary Rehabilitation (CPB 0032, reviewed 2026-03-05)
Aetna considers entry into a medically supervised outpatient pulmonary rehabilitation program medically necessary when the member has a chronic pulmonary disease or another condition that affects pulmonary function, dyspnea at rest or with exertion, reduced exercise tolerance that restricts activities of daily living or work, symptoms that persist despite appropriate medical management, and a moderate to severe functional pulmonary disability. That disability is shown either by a maximal exercise stress test with VO2max of 20 ml/kg/min or less (about 5 METS) or by FEV1, FVC, FEV1/FVC, or DLCO below 60 % of predicted, and the member must be physically able, motivated, and willing to participate. A typical course extends for up to 6 weeks or 36 hours of therapy. Repeat programs are considered not medically necessary, except in connection with lung transplantation or lung volume reduction surgery, and routine, maintenance, or non-skilled care is considered not medically necessary. Pulmonary rehabilitation is considered experimental, investigational, or unproven for all other indications.
Aetna · Identified Aug 12, 2026Medium impact
Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)
Aetna considers automated ambulatory blood pressure monitoring medically necessary when a member meets one of the listed criteria: at least two elevated office readings taken on separate days to identify 'white coat' hypertension; episodic hypertension with symptoms suggesting an adrenal tumor and repeatedly normal office readings; hypotensive symptoms or syncope thought related to antihypertensive medications; syncope evaluated with a 24-hour Holter monitor; nocturnal angina; resistant hypertension before an invasive investigation for secondary causes; or autosomal dominant polycystic kidney disease in children and young adults 30 years of age or younger. Monitoring for less than 24 hours or more than 3 days is not considered medically necessary, and repeat testing is not generally necessary more often than every 6 months. Aetna considers the use experimental, investigational, or unproven for heart failure, for pregnant women who do not meet the criteria, for diagnosing malignant hypertension, for members with an irregular cardiac rhythm such as atrial fibrillation, for routine monitoring to establish a hypertension diagnosis or evaluate treatment response, and for routine use before continuous positive airway pressure (CPAP) therapy.

Watch I21.A9

Get one email when a payer policy names I21.A9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Transmyocardial and Endovascular Laser Revascularization (CPB 0163, reviewed 2026-03-20)

Holter Monitors (CPB 0019, reviewed 2026-03-13)

Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)

Pulmonary Rehabilitation (CPB 0032, reviewed 2026-03-05)

Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)

What insurance policy changes affect code I21.A9?

Which payers have updated policy for code I21.A9?

How do I get notified when code I21.A9 policy changes?

Why do payers change policies for code I21.A9?